MESO vs IMTX Stock Comparison

Mesoblast and Immatics Prices as of Oct 26, 2026 Peers: Industry group
MESO Mesoblast Ltd
$12.39 -18.1% 1M -26.3% 1Y
Market cap
$1.71B
P/E
–
Revenue (TTM)
—
Div. yield
–
Gene and Cell Therapy Healthcare
4 wins
IMTX Immatics N.V.
$7.15 -14.6% 1M -29.8% 1Y
Market cap
$889.47M
P/E
–
Revenue (TTM)
$48.61M
Div. yield
–
Gene and Cell Therapy Healthcare

Head to Head

4 decided of 12

Mesoblast leads on 4 of the 12 questions below (Mesoblast 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMESOIMTXLeader
Larger companyMarket capitalisation $1.71B $889.47M MESO
Cheaper on earningsLower P/E, profitable companies only -27.9x -3.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — –
Faster revenue growthRevenue growth, trailing twelve months — -65.4% –
More profitableNet margin, trailing twelve months — -495.7% –
Better return on capitalReturn on invested capital — — –
Less leveragedLower net debt / EBITDA — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -26.3% -29.8% MESO
Better 5-year returnAnnualised price return, 5 years +0.4%/yr -11.9%/yr MESO
Less volatileAnnualised volatility, 1 year 54.6% 57.7% MESO
Higher overall scoreMean of the five percentile scores vs peers — 36/100 –

Percentile Scorecard

MESOIMTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMESOIMTX
Valuation 71 #183 of 626 28 #449 of 626
Growth – 4 #581 of 604
Profitability – 45 #307 of 555
Financial Health 44 #366 of 658 74 #169 of 658
Shareholder Returns – 26 #271 of 368
Overall – 36
  • MESO ranked among 673 companies in Pharmaceuticals and Biotechnology
  • IMTX ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMESOIMTXSPY
1 month -18.1%-14.6% -0.8%
3 months -14.9%-17.1% +3.5%
6 months -19.2%-37.0% +7.0%
Year to date -31.3%-31.9% +12.2%
1 year -26.3%-29.8% +13.0%
3 years +429.5%-5.3% +86.3%
3 years, per year +74.4%-1.8% +23.1%
5 years +2.2%-46.8% +68.6%
5 years, per year +0.4%-11.9% +11.0%
10 years +52.6%— +258.0%
10 years, per year +4.3%— +13.6%

Risk

MeasureMESOIMTXSPY
Volatility, 1Y 54.6%57.7% 12.7%
Downside volatility, 1Y 54.9%59.2% 12.7%
Beta vs S&P 500, 1Y 1.501.35 1.00
Return / volatility, 1Y -0.48-0.52 1.02
Max drawdown, 5Y -87.9%-75.7% -25.4%
From 52-week high -40.9%-39.8% -1.8%
52-week high $20.96$11.87 $779.14
52-week low $11.95$6.73 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMESOIMTX
P/E now vs peer median -27.9xmedian 17.1x -3.6xmedian 17.1x
P/S now vs peer median 13.3xmedian 8.8x 19.7xmedian 8.8x
EV/EBITDA now vs peer median —median 17.1x -2.0xmedian 17.1x
P/FCF now vs peer median -35.9xmedian 18.0x -3.9xmedian 18.0x
P/B now vs peer median 2.8xmedian 2.1x 2.1xmedian 2.1x
PEG now vs peer median —median 0.31 0.15median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMESOIMTX
Revenue – $48.61M
Operating income – -$264.59M
Net income – -$240.97M
Free cash flow – -$244.28M
R&D – $254.77M
EPS (diluted) – $-1.97
Cash & equivalents $102.91M $265.52M
Total debt $119.24M –
Shares (diluted) 129.49M 122.35M
Enterprise value $1.27B -$1.14B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMESOIMTX
P/E -27.9x -3.6x
P/FCF -35.9x -3.9x
P/Operating cash flow – -4.0x
P/S 13.3x 19.7x
P/B 2.8x 2.1x
P/Tangible book 2.8x 2.1x
EV/EBITDA – -2.0x
EV/EBIT – -1.9x
EV/Revenue – 10.5x
EV/FCF – -2.1x
EV/Operating cash flow – -2.1x
PEG (3Y EPS CAGR) – 0.15

Growth

14 metrics
MetricMESOIMTX
Revenue growth (1Y) – -65.4%
Revenue CAGR (3Y) – -47.1%
Gross profit growth (1Y) – –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) – -176.1%
Operating income CAGR (3Y) – -58.8%
Net income growth (1Y) – -187.4%
Net income CAGR (3Y) – -37.5%
EPS growth (1Y) – -180.7%
EPS CAGR (3Y) – -23.8%
Operating cash flow growth (1Y) – -33.6%
Operating cash flow CAGR (3Y) – -39.1%
Free cash flow growth (1Y) – -29.2%
Free cash flow CAGR (3Y) – -30.7%

Profitability

14 metrics
MetricMESOIMTX
Gross margin – –
EBITDA margin – -515.5%
Operating margin – -544.3%
Pretax margin – -496.3%
Net margin – -495.7%
FCF margin – -502.6%
Operating cash flow margin – -493.8%
Return on equity – -49.2%
Return on assets – -40.9%
Return on invested capital – –
Return on capital employed – -50.5%
Asset turnover – 0.1x
Cash conversion (OCF / net income) – 1.0x
Stock comp / revenue – 42.1%

Financial Health

11 metrics
MetricMESOIMTX
Debt / assets 15.4% –
Debt / equity 0.2x –
Net debt / EBITDA – –
Debt / FCF – –
Liabilities / assets 26.5% 17.7%
Equity / assets 73.5% 82.3%
Interest coverage – -3.2x
Current ratio 2.4x 7.5x
Quick ratio 2.0x 7.0x
Cash ratio 1.3x 6.9x
Altman Z-score – 2.67

Shareholder Returns

7 metrics
MetricMESOIMTX
Dividend yield – –
Net buyback yield – -15.8%
Shareholder yield – -15.8%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMESOIMTX
EPS, next fiscal year $-0.15FY2027 $-2.10FY2026
Revenue, next fiscal year $188.99MFY2027 $40.64MFY2026
Revenue growth, next FY +57.2%FY2027 -28.4%FY2026
Revenue growth, the year after +110.3% -11.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMESOIMTX
Held by institutions 3.0% 81.6%
Institutions holding 73 83
Change in shares held, QoQ +17.7% -7.8%
Institutions buying 34 37
Institutions selling 20 33
Buyers to sellers 1.70 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MESOIMTX
MESO 1.00 0.19
IMTX 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MESO and IMTX?

Mesoblast (MESO) is the largest by market capitalisation: Mesoblast (MESO) $1.71B, Immatics (IMTX) $889.47M.

Which stock has performed better?

Over the past year Mesoblast (MESO) returned the most: Mesoblast (MESO) -26.3%, Immatics (IMTX) -29.8%. Over five years, Mesoblast (MESO) compounded fastest (Mesoblast (MESO) +0.4%/yr, Immatics (IMTX) -11.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Mesoblast (MESO) has been the steadiest (Mesoblast (MESO) 54.6%, Immatics (IMTX) 57.7%). Volatility measures how widely the price swings, not the risk of the business.

Do MESO and IMTX move together?

Their daily returns over the past year have a correlation of 0.19, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, MESO and IMTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mesoblast (MESO) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.